Okta, Inc.
$29.48B- Market cap
- $29.89B
- Debt
- +$445.00M
- Cash
- −$858.00M
Capital structure 99% equity / 1% debt · EV / Revenue 10.10x · EV / EBITDA 83.98x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $29.89B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2024 ·
Decision snapshot: OKTA stock price at premium vs ZNTL $170.60 current versus $70.39 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZNTL's multiple
Implied fair value · at OKTA's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OKTA FY 2026 (ended Jan 31, 2026) · ZNTL FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 10.10x · EV / EBITDA 83.98x
Capital structure 78% equity / 22% debt · EV / Revenue 4.96x
OKTA carries the larger enterprise value at $29.48B against $334.64M; ZNTL trades on the lower EV / Revenue multiple (4.96x vs 10.10x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Okta, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.06x
0.24x
Net debt / EBITDA
Leverage against operating earnings
-1.18x
-0.29x
Cash and equivalents
Liquid reserves on the balance sheet
$858.00M
$33.90M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cloudflare, Inc.
OKTA vs NET
Zscaler, Inc.
OKTA vs ZS
CrowdStrike Holdings, Inc.
OKTA vs CRWD
CyberArk Software Ltd.
OKTA vs CYBR
Arcus Biosciences, Inc.
OKTA vs RCUS
Repare Therapeutics Inc.
OKTA vs RPTX
IDEAYA Biosciences, Inc.
OKTA vs IDYA
Mersana Therapeutics, Inc.
OKTA vs MRSN
EXELIXIS, INC.
OKTA vs EXEL
$445.00M
$82.57M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.